Table 3.
Volunteer ID# | Code
|
Serum neutralizing antibody titer on indicated day againsta:
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
TBEV/DEN4Δ30
|
LGT
|
||||||||||
1-st dose | 2-nd dose | 0 | 28 | 42 | 180 | 0 | 28 | 42 | 180 | ||
19 | Placebo | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | |
26 | Placebo | Placebo | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | |
| |||||||||||
12 | Placebo | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | |
16 | Placebo | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | < 5 | |
25 | Placebo | Vaccine | < 5 | 298 | 568 | 68 | < 5 | 1008 | 649 | 147 | |
| |||||||||||
01 | Vaccine | Vaccine | < 5 | 6 | 5 | < 5 | 19 | 39 | 22 | 28 | |
03 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 17 | 11 | 5 | |
04 | Vaccine | Vaccine | 38 | 36 | 37 | 36 | 157 | 187 | 164 | 83 | |
05 | Vaccine | Vaccine | 39 | 51 | 31 | 28 | 289 | 446 | 381 | 86 | |
08 | Vaccine | Vaccine | 14 | 39 | 33 | 28 | 28 | 100 | 88 | 26 | |
10 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 6 | 5 | 7 | |
11 | Vaccine | Vaccine | 8 | 9 | 5 | 37 | 34 | 48 | 52 | 56 | |
13 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | 14 | 29 | 31 | 20 | |
17 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 58 | 92 | 30 | |
18 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | 11 | 21 | 14 | 13 | |
20 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | < 5 | 16 | 14 | < 5 | |
22 | Vaccine | Vaccine | < 5 | < 5 | < 5 | < 5 | 10 | 36 | 44 | 11 | |
23 | Vaccine | Vaccine | 35 | 30 | 76 | 10 | 55 | 85 | 67 | 49 | |
27 | Vaccine | Vaccine | < 5 | < 5 | 5 | < 5 | 5 | 11 | 12 | 7 | |
28 | Vaccine | Vaccine | < 5 | 7 | < 5 | < 5 | < 5 | 50 | 19 | < 5 | |
29 | Vaccine | Vaccine | 17 | 11 | 9 | 14 | 127 | 163 | 164 | 80 | |
| |||||||||||
GMTb: | 8 | 9 | 8 | 8 | 17 | 45 | 38 | 19 | |||
|
|
||||||||||
Seropositive: | 6/16 | 8/16 | 8/16 | 6/16 | 11/16 | 16/16 | 16/16 | 14/16 | |||
38% | 50% | 50% | 38% | 69% | 100% | 100% | 88% | ||||
|
|
||||||||||
Seroconversion: | 0/16 | 0/16 | 1/16 | 2/16 | 2/16 | 1/16 | |||||
0% | 0% | 6% | 13% | 13% | 6% | ||||||
1/16 = 6% | 3/16 = 19% |
Plaque reduction (60%) neutralizing antibody titers (reciprocal) were determined against wild-type LGT TP21 strain or chimeric TBEV/DEN4Δ30 virus as indicated.
GMT, geometric mean titers (reciprocal) are calculated for 16 vaccine recipients and does not include 3 volunteers who received placebo in primary inoculation and vaccine in second inoculation. Seroconversion (indicated by shading) is defined as a ≥4-fold rise in serum neutralizing antibody titer on day 28, 42, or 180 after booster vaccination, compared with a titer observed in serum of volunteers prior to receive a booster dose of LGT/DEN4 vaccine.